A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis
Identifieur interne : 005F07 ( Main/Exploration ); précédent : 005F06; suivant : 005F08A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis
Auteurs : Warner Carr [États-Unis] ; Jonathan Bernstein [États-Unis] ; Phil Lieberman [Égypte] ; Eli Meltzer [Bolivie] ; Claus Bachert ; David Price [Australie] ; Ullrich Munzel [Allemagne] ; Jean Bousquet [France]Source :
- Journal of allergy and clinical immunology [ 0091-6749 ] ; 2012.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Allergie, Immunologie.
English descriptors
- KwdEn :
Abstract
Background: Moderate-to-severe allergic rhinitis (AR) is a challenge to treat, with many patients using multiple therapies and achieving limited symptom control. More effective therapies must be developed and tested in well-controlled, randomized, prospective studies with a direct comparison to current standards. Objectives: The aim of these studies was to investigate the efficacy of MP29-02 (a novel formulation of azelastine and fluticasone propionate [FP]) in patients with moderate-to-severe seasonal allergic rhinitis (SAR) and to compare its efficacy with 2 first-line therapies (ie, intranasal azelastine and intranasal FP) in this population. Methods: Three thousand three hundred ninety-eight patients (≥12 years old) with moderate-to-severe SAR were enrolled into 3 multicenter, randomized, double-blind, placebo- and active-controlled, parallel-group trials (MP4002 [NCT00651118], MP4004 [NCT00740792], and MP4006 [NCT00883168]). Each trial was conducted for 14 days during different allergy seasons. The primary efficacy variable was the sum of the morning and evening change from baseline in reflective total nasal symptom score (range, 0-24) over the treatment period. Outcomes for the meta-analysis included efficacy according to disease severity and time to response in relevant responder criteria. Results: In the meta-analysis MP29-02 reduced the mean reflective total nasal symptom score from baseline (-5.7 [SD, 5.3]) more than FP (-5.1 [SD, 4.9], P < .001), azelastine (-4.4 [SD, 4.8], P < .001), or placebo (-3.0 [SD, 4.2], P < .001). This benefit was observed from the first day of assessment, with improvement in each individual nasal symptom, even in the patients with the most severe disease. MP29-02 achieved response consistently days earlier and showed greater efficacy in patients with moderate-to-severe rhinitis than FP and azelastine. Conclusions: MP29-02 represents a novel therapy that demonstrated superiority to 2 first-line therapies for AR. Patients with moderate-to-severe SAR achieved better control, and their symptoms were controlled earlier with MP29-02 than with recommended medications according to guidelines.
Affiliations:
- Allemagne, Australie, Bolivie, France, Égypte, États-Unis
- Californie, Languedoc-Roussillon, Occitanie (région administrative)
- Montpellier, San Diego
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 001377
- to stream PascalFrancis, to step Curation: 004B36
- to stream PascalFrancis, to step Checkpoint: 001403
- to stream Main, to step Merge: 006238
- to stream Main, to step Curation: 005F07
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis</title><author><name sortKey="Carr, Warner" sort="Carr, Warner" uniqKey="Carr W" first="Warner" last="Carr">Warner Carr</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Allergy and Asthma Associates of Southern California</s1><s2>Mission Viejo</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Allergy and Asthma Associates of Southern California</wicri:noRegion></affiliation></author><author><name sortKey="Bernstein, Jonathan" sort="Bernstein, Jonathan" uniqKey="Bernstein J" first="Jonathan" last="Bernstein">Jonathan Bernstein</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Internal Medicine, University of Cincinnati College of Medicine</s1><s2>Cincinnati</s2><s3>USA</s3><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Cincinnati</wicri:noRegion></affiliation></author><author><name sortKey="Lieberman, Phil" sort="Lieberman, Phil" uniqKey="Lieberman P" first="Phil" last="Lieberman">Phil Lieberman</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Internal Medicine & Pediatrics, University of Tennessee College of Medicine</s1><s2>Memphis</s2><s3>EGY</s3><sZ>3 aut.</sZ></inist:fA14><country>Égypte</country><wicri:noRegion>Memphis</wicri:noRegion></affiliation></author><author><name sortKey="Meltzer, Eli" sort="Meltzer, Eli" uniqKey="Meltzer E" first="Eli" last="Meltzer">Eli Meltzer</name><affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Allergy and Asthma Medical Group and Research Center</s1><s2>San Diego</s2><s3>BOL</s3><sZ>4 aut.</sZ></inist:fA14><country>Bolivie</country><placeName><settlement type="city">San Diego</settlement><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Bachert, Claus" sort="Bachert, Claus" uniqKey="Bachert C" first="Claus" last="Bachert">Claus Bachert</name><affiliation><inist:fA14 i1="05"><s1>Department of Oto-Rhino Laryngology, Ghent University Hospital</s1><s3>INC</s3><sZ>5 aut.</sZ></inist:fA14><wicri:noCountry>INC</wicri:noCountry></affiliation></author><author><name sortKey="Price, David" sort="Price, David" uniqKey="Price D" first="David" last="Price">David Price</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of General Practice & Primary Care. University of Aberdeen</s1><s3>AUS</s3><sZ>6 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Department of General Practice & Primary Care. University of Aberdeen</wicri:noRegion></affiliation></author><author><name sortKey="Munzel, Ullrich" sort="Munzel, Ullrich" uniqKey="Munzel U" first="Ullrich" last="Munzel">Ullrich Munzel</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>MEDA Pharma GmbH & Co. KG, Biostatis<sub>t</sub>ics & Information</s1><s2>Bad Homburg</s2><s3>DEU</s3><sZ>7 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>Bad Homburg</wicri:noRegion><wicri:noRegion>Bad Homburg</wicri:noRegion></affiliation></author><author><name sortKey="Bousquet, Jean" sort="Bousquet, Jean" uniqKey="Bousquet J" first="Jean" last="Bousquet">Jean Bousquet</name><affiliation wicri:level="3"><inist:fA14 i1="08"><s1>Department of Respiratory Diseases. Hopital Arnaud de Villeneuve University Hospital</s1><s2>Montpellier</s2><s3>FRA</s3><sZ>8 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">12-0219127</idno><date when="2012">2012</date><idno type="stanalyst">PASCAL 12-0219127 INIST</idno><idno type="RBID">Pascal:12-0219127</idno><idno type="wicri:Area/PascalFrancis/Corpus">001377</idno><idno type="wicri:Area/PascalFrancis/Curation">004B36</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001403</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001403</idno><idno type="wicri:doubleKey">0091-6749:2012:Carr W:a:novel:intranasal</idno><idno type="wicri:Area/Main/Merge">006238</idno><idno type="wicri:Area/Main/Curation">005F07</idno><idno type="wicri:Area/Main/Exploration">005F07</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis</title><author><name sortKey="Carr, Warner" sort="Carr, Warner" uniqKey="Carr W" first="Warner" last="Carr">Warner Carr</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Allergy and Asthma Associates of Southern California</s1><s2>Mission Viejo</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Allergy and Asthma Associates of Southern California</wicri:noRegion></affiliation></author><author><name sortKey="Bernstein, Jonathan" sort="Bernstein, Jonathan" uniqKey="Bernstein J" first="Jonathan" last="Bernstein">Jonathan Bernstein</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Internal Medicine, University of Cincinnati College of Medicine</s1><s2>Cincinnati</s2><s3>USA</s3><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Cincinnati</wicri:noRegion></affiliation></author><author><name sortKey="Lieberman, Phil" sort="Lieberman, Phil" uniqKey="Lieberman P" first="Phil" last="Lieberman">Phil Lieberman</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Internal Medicine & Pediatrics, University of Tennessee College of Medicine</s1><s2>Memphis</s2><s3>EGY</s3><sZ>3 aut.</sZ></inist:fA14><country>Égypte</country><wicri:noRegion>Memphis</wicri:noRegion></affiliation></author><author><name sortKey="Meltzer, Eli" sort="Meltzer, Eli" uniqKey="Meltzer E" first="Eli" last="Meltzer">Eli Meltzer</name><affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Allergy and Asthma Medical Group and Research Center</s1><s2>San Diego</s2><s3>BOL</s3><sZ>4 aut.</sZ></inist:fA14><country>Bolivie</country><placeName><settlement type="city">San Diego</settlement><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Bachert, Claus" sort="Bachert, Claus" uniqKey="Bachert C" first="Claus" last="Bachert">Claus Bachert</name><affiliation><inist:fA14 i1="05"><s1>Department of Oto-Rhino Laryngology, Ghent University Hospital</s1><s3>INC</s3><sZ>5 aut.</sZ></inist:fA14><wicri:noCountry>INC</wicri:noCountry></affiliation></author><author><name sortKey="Price, David" sort="Price, David" uniqKey="Price D" first="David" last="Price">David Price</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of General Practice & Primary Care. University of Aberdeen</s1><s3>AUS</s3><sZ>6 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Department of General Practice & Primary Care. University of Aberdeen</wicri:noRegion></affiliation></author><author><name sortKey="Munzel, Ullrich" sort="Munzel, Ullrich" uniqKey="Munzel U" first="Ullrich" last="Munzel">Ullrich Munzel</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>MEDA Pharma GmbH & Co. KG, Biostatis<sub>t</sub>ics & Information</s1><s2>Bad Homburg</s2><s3>DEU</s3><sZ>7 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>Bad Homburg</wicri:noRegion><wicri:noRegion>Bad Homburg</wicri:noRegion></affiliation></author><author><name sortKey="Bousquet, Jean" sort="Bousquet, Jean" uniqKey="Bousquet J" first="Jean" last="Bousquet">Jean Bousquet</name><affiliation wicri:level="3"><inist:fA14 i1="08"><s1>Department of Respiratory Diseases. Hopital Arnaud de Villeneuve University Hospital</s1><s2>Montpellier</s2><s3>FRA</s3><sZ>8 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author></analytic><series><title level="j" type="main">Journal of allergy and clinical immunology</title><title level="j" type="abbreviated">J. allergy clin. immunol.</title><idno type="ISSN">0091-6749</idno><imprint><date when="2012">2012</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Journal of allergy and clinical immunology</title><title level="j" type="abbreviated">J. allergy clin. immunol.</title><idno type="ISSN">0091-6749</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Allergy</term><term>Azelastine</term><term>Fluticasone</term><term>Immunology</term><term>Immunopathology</term><term>Intranasal administration</term><term>Rhinitis</term><term>Treatment</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Allergie</term><term>Rhinite</term><term>Voie intranasale</term><term>Traitement</term><term>Azélastine</term><term>Fluticasone</term><term>Immunologie</term><term>Immunopathologie</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Allergie</term><term>Immunologie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background: Moderate-to-severe allergic rhinitis (AR) is a challenge to treat, with many patients using multiple therapies and achieving limited symptom control. More effective therapies must be developed and tested in well-controlled, randomized, prospective studies with a direct comparison to current standards. Objectives: The aim of these studies was to investigate the efficacy of MP29-02 (a novel formulation of azelastine and fluticasone propionate [FP]) in patients with moderate-to-severe seasonal allergic rhinitis (SAR) and to compare its efficacy with 2 first-line therapies (ie, intranasal azelastine and intranasal FP) in this population. Methods: Three thousand three hundred ninety-eight patients (≥12 years old) with moderate-to-severe SAR were enrolled into 3 multicenter, randomized, double-blind, placebo- and active-controlled, parallel-group trials (MP4002 [NCT00651118], MP4004 [NCT00740792], and MP4006 [NCT00883168]). Each trial was conducted for 14 days during different allergy seasons. The primary efficacy variable was the sum of the morning and evening change from baseline in reflective total nasal symptom score (range, 0-24) over the treatment period. Outcomes for the meta-analysis included efficacy according to disease severity and time to response in relevant responder criteria. Results: In the meta-analysis MP29-02 reduced the mean reflective total nasal symptom score from baseline (-5.7 [SD, 5.3]) more than FP (-5.1 [SD, 4.9], P < .001), azelastine (-4.4 [SD, 4.8], P < .001), or placebo (-3.0 [SD, 4.2], P < .001). This benefit was observed from the first day of assessment, with improvement in each individual nasal symptom, even in the patients with the most severe disease. MP29-02 achieved response consistently days earlier and showed greater efficacy in patients with moderate-to-severe rhinitis than FP and azelastine. Conclusions: MP29-02 represents a novel therapy that demonstrated superiority to 2 first-line therapies for AR. Patients with moderate-to-severe SAR achieved better control, and their symptoms were controlled earlier with MP29-02 than with recommended medications according to guidelines.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Bolivie</li><li>France</li><li>Égypte</li><li>États-Unis</li></country><region><li>Californie</li><li>Languedoc-Roussillon</li><li>Occitanie (région administrative)</li></region><settlement><li>Montpellier</li><li>San Diego</li></settlement></list><tree><noCountry><name sortKey="Bachert, Claus" sort="Bachert, Claus" uniqKey="Bachert C" first="Claus" last="Bachert">Claus Bachert</name></noCountry><country name="États-Unis"><noRegion><name sortKey="Carr, Warner" sort="Carr, Warner" uniqKey="Carr W" first="Warner" last="Carr">Warner Carr</name></noRegion><name sortKey="Bernstein, Jonathan" sort="Bernstein, Jonathan" uniqKey="Bernstein J" first="Jonathan" last="Bernstein">Jonathan Bernstein</name></country><country name="Égypte"><noRegion><name sortKey="Lieberman, Phil" sort="Lieberman, Phil" uniqKey="Lieberman P" first="Phil" last="Lieberman">Phil Lieberman</name></noRegion></country><country name="Bolivie"><region name="Californie"><name sortKey="Meltzer, Eli" sort="Meltzer, Eli" uniqKey="Meltzer E" first="Eli" last="Meltzer">Eli Meltzer</name></region></country><country name="Australie"><noRegion><name sortKey="Price, David" sort="Price, David" uniqKey="Price D" first="David" last="Price">David Price</name></noRegion></country><country name="Allemagne"><noRegion><name sortKey="Munzel, Ullrich" sort="Munzel, Ullrich" uniqKey="Munzel U" first="Ullrich" last="Munzel">Ullrich Munzel</name></noRegion></country><country name="France"><region name="Occitanie (région administrative)"><name sortKey="Bousquet, Jean" sort="Bousquet, Jean" uniqKey="Bousquet J" first="Jean" last="Bousquet">Jean Bousquet</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005F07 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005F07 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:12-0219127
|texte= A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis
}}
| This area was generated with Dilib version V0.6.33. |  |